ICICI Securities keeps Hold on Sudeep Pharma after 75% rally
In short
Sudeep Pharma shares are up about 75% from their IPO price. ICICI Securities still has a Hold rating and raised its target price to ₹1,000.
The broker says the market may already be pricing in the company’s battery materials business. It is not stated what the current share price is or how much more the stock could move.
What the reporting says
Sudeep Pharma shares have climbed nearly 75% above their IPO price, and ICICI Securities kept a Hold rating while raising its target price to ₹1,000. The brokerage said expectations for the company’s emerging battery materials business are already reflected in the valuation. The reporting does not state the current share price or whether the target implies upside or downside from here.
Why it matters
Sudeep Pharma’s shares have risen nearly 75% above the IPO price, according to the reporting, and ICICI Securities kept a Hold recommendation while lifting its target to ₹1,000. The key reason given is that the market already appears to value the company’s emerging battery materials business. The immediate implication is limited near-term enthusiasm from the broker, but the reporting does not disclose the current trading level.